ALVESCO

Compare ALVESCO  to:
Compare
Compare

Generic Name for ALVESCO

Ciclesonide 80mcg/inh, 160mcg/inh; metered dose aerosol.

Legal Classification:

Rx

Pharmacological Class for ALVESCO

Steroid.

Manufacturer of ALVESCO

Sepracor, Inc.

Indications for ALVESCO

Maintenance treatment of asthma as prophylactic therapy in patients ≥12 years of age.

Adult dose for ALVESCO

Previously on bronchodilators alone: initially 80mcg twice daily, max 160mcg twice daily. Previously on inhaled corticosteroids: initially 80mcg twice daily; max 320mcg twice daily. Previously on oral corticosteroids (see literature): 320mcg twice daily. Rinse mouth after use; avoid eyes.

Children's dosing for ALVESCO

Not recommended.

Contraindications for ALVESCO

Not for primary treatment of acute attack.

Warnings/Precautions for ALVESCO

Infections. If exposed to chickenpox or measles, consider immuneglobulin prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with inhaled corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude). Monitor for hypercorticism and HPA axis suppression (if occur reduce dose gradually). Monitor for growth suppression in children. Monitor for changes in vision, increased intraocular pressure, cataracts. Pregnancy (Cat.C). Nursing mothers.

Adverse Reactions for ALVESCO

Headache, nasopharyngitis, sinusitis, throat pain, upper respiratory infection, arthralgia, nasal congestion, back pain; rare: bronchospasm, immunosuppression, glaucoma, cataracts, oral candidiasis, decreased bone mineral density.

How is ALVESCO supplied?

Inhaler—6.1g (60 inh)

Related Disease:

Asthma~antiasthmatics

Related Resources

FDA warns of stolen Advair Diskus product

July 19, 2010

The FDA has warned healthcare professionals and consumers not to use certain Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhalers stolen from a distribution warehouse in 2009 which have been found recently in some pharmacies.

Glassia approved for treating alpha 1 antitrypsin deficiency

July 06, 2010

Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).

Dulera approved for the treatment of asthma

June 24, 2010

Merck announced that the FDA has approved Dulera (mometasone furoate and formoterol fumarate dihydrate) inhalation aerosol for the treatment of asthma in patients ≥12 years of age.

Phase 2b study of Aerovant for the treatment of eosinophilic asthma

June 08, 2010

Aerovance Inc. announced top-line results from its Phase 2b trial demonstrating that Aerovant (pitrakinra) is effective in a pre-defined subset of patients with eosinophilic asthma.

AeroChamber Plus Flow-Vu anti-static valved holding chamber available

June 04, 2010

Forest Pharmaceuticals and Lupin Pharmaceuticals have made available the AeroChamber Plus Flow-Vu anti-static valved holding chamber for use with metered dose inhalers (MDI).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions